Gabriel T. Schnickel

Gabriel T. Schnickel

Auto-generated profile, based on publicly available information

Gabriel T. Schnickel

Division of Hepatobiliary and Transplant Surgery, Department of Surgery, University of California San Diego

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2003 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
MNMark R Nehler
Mark R Nehler
JCJoseph R Coll
Joseph R Coll
WHWilliam R Hiatt
William R Hiatt
JRJudith G Regensteiner
Judith G Regensteiner
GSGabriel T Schnickel
Gabriel T Schnickel
WKWilliam C Krupski
William C Krupski

1 December 2009 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
TKTanveer A. Khan
Tanveer A. Khan
GSGabriel Schnickel
Gabriel Schnickel
DRDavid Ross
David Ross
SBSam Bastani
Sam Bastani
HLHillel Laks
Hillel Laks
AAAbbas Ardehali
Abbas Ardehali

1 April 2013 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
HYHasan Yersiz
Hasan Yersiz
CLConey Lee
Coney Lee
FKFady M. Kaldas
Fady M. Kaldas
JHJohnny C. Hong
Johnny C. Hong
ARAbbas Rana
Abbas Rana
HPHenrik Petrowsky
Henrik Petrowsky

8 September 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
PTParissa Tabrizian
Parissa Tabrizian
MHMatthew L. Holzner
Matthew L. Holzner
VAVeeral Ajmera
Veeral Ajmera
AKAmy K. Kim
Amy K. Kim
KZKali Zhou
Kali Zhou
NMNeil Mehta MD
Neil Mehta MD

8 February 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
GSGabriel T. Schnickel
Gabriel T. Schnickel
KFKassandra Fabbri
Kassandra Fabbri
MHMojgan Hosseini
Mojgan Hosseini
MMMichael Misel
Michael Misel
JBJennifer Berumen
Jennifer Berumen
VAVeeral Ajmera
Veeral Ajmera
Limited case series describe conflicting results regarding the safety of checkpoint inhibitors (CPI) prior to liver transplantation (LT). We reviewed single-center data on all consecutive patients who underwent LT for hepatocellular carcinoma treated with CPI between January 1, 2018, and January 30, 2021. Time from CPI to LT, immunosuppression, biopsy-proven acute cellular rejection (BPACR), graft loss and death were evaluated. Five patients with a mean age 65 (range 61–71) years underwent LT after CPI with nivolumab. Time from last CPI to LT ranged from 0.3 to 11 months. Two patients with 3 months from the last dose of CPI had BPACR. In conclusion, pretransplant use of CPIs, particularly within 90 days of LT, was associated with BPACR and immune-mediated hepatic necrosis. Future multicenter studies should consider a sufficient interval from the last dose of CPI to LT to mitigate the risk for adverse immune-mediated outcomes and graft loss.

5 March 2025 in Hepatology
Verified
Journal Article
Open access
Beat MoeckliBeat Moeckli
Beat Moeckli
CWCharles-Henri Wassmer
Charles-Henri Wassmer
SHSofia El Hajji
Sofia El Hajji
RKRohan Kumar
Rohan Kumar
JRJoana Rodrigues Ribeiro
Joana Rodrigues Ribeiro
CTChristian Toso
Christian Toso
Background and Aims: Immune checkpoint inhibitors (ICIs) are increasingly used in patients with advanced HCC patients awaiting liver transplantation (LT). However, concerns about the risk of posttransplant rejection persist. Approach and Results: We conducted an international retrospective cohort study including 119 HCC patients who received ICIs prior to LT. We analyzed the incidence of allograft rejection, graft loss, and posttransplant recurrence with a particular focus on the washout period between the last ICI dose and LT. In this study, 24 of the 119 (20.2%) patients experienced allograft rejection with a median time to rejection of 9 days (IQR 6–10) post-LT. A linear relationship was observed between shorter washout periods and higher rejection risk. Washout periods <30 days (OR: 21.3, 95% CI: 5.93–103, p<0.001) and between 30 and 50 days (OR: 9.48, 95% CI 2.47–46.8, p=0.002) were significantly associated with higher rejection rates in the univariate analysis compared to the washout period above 50 days. Graft loss as a result of rejection occurred in 6 patients (25%) with rejection. No factors related to grafts were associated with rejection. A longer washout period was not associated with a lower recurrence-free survival posttransplantation at 36 months (71% vs. 67%, p=0.71). Conclusions: Our findings suggest that a washout period longer than 50 days for ICIs before LT appears to be safe with respect to rejection risk. While these results may help guide clinical decision-making, future prospective studies are essential to establish definitive guidelines.